Physician profile
David Harries
NPI 1104924109
$3,182.05
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $85.09 · 2021: $1,158 · 2022: $56.09 · 2023: $138 · 2024: $16.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $1,480.29 | 2019-2021 | |
| Nevro Corp. | $368.69 | 2019-2021 | |
| Medtronic USA, INC. | $280.36 | 2019-2020 | |
| Medtronic, INC. | $182.27 | 2021-2023 | Intellis Adaptivestim |
| Abbott Laboratories | $165.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $141.67 | 2019 | |
| Allergan, INC. | $119.40 | 2019-2022 | |
| Stimwave Technologies Incorporated | $99.46 | 2019 | |
| Amgen INC. | $64.40 | 2019-2020 | |
| Relievant Medsystems, INC. | $61.46 | 2019 | |
| Lilly USA, LLC | $58.49 | 2019-2020 | |
| Stryker Corporation | $39.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.60 | 2021 | |
| Tersera Therapeutics LLC | $22.76 | 2021 | |
| Abbvie INC. | $16.87 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.92 | 2019 | |
| Avanos Medical | $11.96 | 2020 | |
| Boston Scientific Corporation | $11.89 | 2019 | |
| Pfizer INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.